Advancing Early Breast Cancer Decision-Making with Dr. William Audeh – Health Innovation Matters
Michael chats with Dr. William Audeh, Chief Medical Officer at Agendia. Together, they discuss recent advancements in genomic testing for early-stage breast cancer, how Agendia’s MammaPrint® and BluePrint® genomic assays go beyond answering the question of “chemo or no chemo,” how decisions based on genomic insights offer improved precision in guiding treatment decisions for patients and their physicians, the future of genomic testing, how the FLEX Study is helping answer clinical questions, and much more.
To learn more about Agendia, MammaPrint, and BluePrint, visit www.Agendia.com.
About Our Guest
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh also served as Director of the Medical Oncology Training Program for Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai, and is Associate Clinical Professor of Medicine at the UCLA David Geffen School of Medicine. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.
Dr. Audeh received his medical degree from the University of Iowa and an M.S. Degree in Genetics from the University of Minnesota. He went on to complete his residency in Internal Medicine as well as a fellowship in Medical Oncology at Stanford University Medical Center. He is board certified on internal medicine and medical oncology, and is a member of the American Society of Clinical Oncology and American Association of Cancer Research.
Health Innovation Matters 